| Literature DB >> 34559583 |
Blaise Cozene1, Nadia Sadanandan2, Jeffrey Farooq3, Chase Kingsbury3, You Jeong Park3, Zhen-Jie Wang3, Alexa Moscatello3, Madeline Saft4, Justin Cho3, Bella Gonzales-Portillo5, Cesar V Borlongan3.
Abstract
Traumatic brain injury (TBI) is a pervasive and damaging form of acquired brain injury (ABI). Acute, subacute, and chronic cell death processes, as a result of TBI, contribute to the disease progression and exacerbate outcomes. Extended neuroinflammation can worsen secondary degradation of brain function and structure. Mesenchymal stem cell transplantation has surfaced as a viable approach as a TBI therapeutic due to its immunomodulatory and regenerative features. This article examines the role of inflammation and cell death in ABI as well as the effectiveness of bone marrow-derived mesenchymal stem/stromal cell (BM-MSC) transplants as a treatment for TBI. Furthermore, we analyze new studies featuring transplanted BM-MSCs as a neurorestorative and anti-inflammatory therapy for TBI patients. Although clinical trials support BM-MSC transplants as a viable TBI treatment due to their promising regenerative characteristics, further investigation is imperative to uncover innovative brain repair pathways associated with cell-based therapy as stand-alone or as combination treatments.Entities:
Keywords: acquired brain injury; bone marrow-derived mesenchymal stem cells; clinical trials; inflammation; preclinical studies; traumatic brain injury
Mesh:
Year: 2021 PMID: 34559583 PMCID: PMC8485159 DOI: 10.1177/09636897211035715
Source DB: PubMed Journal: Cell Transplant ISSN: 0963-6897 Impact factor: 4.064